These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28904036)

  • 1. Sacubitril-valsartan: novel therapy for heart failure.
    Sehn E; McDonald T; Lindblad AJ
    Can Fam Physician; 2017 Sep; 63(9):697. PubMed ID: 28904036
    [No Abstract]   [Full Text] [Related]  

  • 2. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.
    Salah HM; Fudim M; Al'Aref SJ; Khan MS; Almarzooq ZI; Devabhaktuni SR; Mentz RJ; Butler J; Greene SJ
    Am J Cardiol; 2021 Apr; 145():165-168. PubMed ID: 33529619
    [No Abstract]   [Full Text] [Related]  

  • 4. What will be the impact of sacubitril/valsartan in clinical practice?
    Metra M
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e88-e90. PubMed ID: 29084021
    [No Abstract]   [Full Text] [Related]  

  • 5. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice.
    Morillas-Climent H; Seller-Moya J; Vicedo-López Á; Galcerá-Jornet E; Alania-Torres E; Rodríguez-Pichardo Y; Larumbe-Rodríguez A; Valle-Muñoz A
    J Comp Eff Res; 2019 Jul; 8(9):685-697. PubMed ID: 31290687
    [No Abstract]   [Full Text] [Related]  

  • 6. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?
    Mair J; Lindahl B; Giannitsis E; Huber K; Thygesen K; Plebani M; Möckel M; Müller C; Jaffe AS;
    Eur Heart J Acute Cardiovasc Care; 2017 Jun; 6(4):321-328. PubMed ID: 26758541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.
    López-Azor JC; Vicent L; Valero-Masa MJ; Esteban-Fernández A; Gómez-Bueno M; Pérez Á; Díez-Villanueva P; De-Juan J; Manuel-Iniesta Á; Bover R; Del Prado S; Martínez-Sellés M
    ESC Heart Fail; 2019 Dec; 6(6):1161-1166. PubMed ID: 31701680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of sacubitril-valsartan for the treatment of chronic heart failure.
    Tyler JM; Teerlink JR
    Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
    Pogge EK; Davis LE
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    McCormack PL
    Drugs; 2016 Mar; 76(3):387-96. PubMed ID: 26873495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
    Srivastava PK; Fonarow GC
    JAMA Cardiol; 2019 Mar; 4(3):195-196. PubMed ID: 30810709
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
    Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update on the clinical application of valsartan/sacubitril in patients with heart failure].
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):538-541. PubMed ID: 28648033
    [No Abstract]   [Full Text] [Related]  

  • 17. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
    Jhund PS; McMurray JJ
    Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
    Liu RC
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
    Ahn R; Prasad V
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):633-635. PubMed ID: 30232657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.